



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

*zo*

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/550,837      | 08/02/2006  | Michael Crothers     | 833.012             | 6054             |

23598 7590 06/22/2007  
BOYLE FREDRICKSON NEWHOLM STEIN & GRATZ, S.C.  
250 E. WISCONSIN AVENUE  
SUITE 1030  
MILWAUKEE, WI 53202

|          |
|----------|
| EXAMINER |
|----------|

MI, QIUWEN

|          |              |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1655

|                   |               |
|-------------------|---------------|
| NOTIFICATION DATE | DELIVERY MODE |
|-------------------|---------------|

06/22/2007

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@boylefred.com

|                              |                                      |  |  |
|------------------------------|--------------------------------------|--|--|
| <b>Office Action Summary</b> | <b>Application No.</b><br>10/550,837 | <b>Applicant(s)</b><br>CROTHERS ET AL. |  |
|                              | <b>Examiner</b><br>Qiuwen Mi         | <b>Art Unit</b><br>1655                |  |

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 16 May 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-22 is/are pending in the application.
- 4a) Of the above claim(s) 9-11 and 19-22 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-8 and 12-18 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
     Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
     Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### **Election/Restrictions**

Applicant's election with traverse of claims 1-18 and the species *Ascomycotina* in the reply filed on 5/16/2007 is acknowledged.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: As Belanger et al (US 5,443,981) teach a special technical feature of a crude membrane fraction of Fungus *Acremonium typhinum* which is reactive with BCA and the endoproteolytic activity is inhibited by the protease inhibitor PMSF (col 1, lines 60-67), therefore, there is no special technical feature in the application. Accordingly the groups are not so linked as to form a single general concept under PCT Rule 13.1., and therefore lack of unity of invention exists.

Applicant is reminded of the extensive literature search in biotechnology which is not co-extensive.

The requirement is still deemed proper and is therefore made FINAL.

Claims 9-11, and 19-22 are withdrawn from further consideration as being drawn to nonelected inventions.

### **Specification Objections**

Art Unit: 1655

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

### **Claim Rejections –35 USC § 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-6, and 12-18 are rejected under 35 USC § 102 (b) as being anticipated by Belanger et al (US 5,443,981).

Belanger et al teach a crude membrane fraction of Fungus *Acremonium typhinum* (contains a fungal cell or fragment) exhibiting endoproteolytic activity which has a function of insect deterrence (thus a medicament)(col 1, lines 45-50), and the fraction is reactive with BCA (pharmaceutically active compound, peptide, having a hydrophilic moiety). The endoproteolytic activity is inhibited by the protease inhibitor PMSF (col 1, lines 60-67). Fig. 4 shows the SDS-

Art Unit: 1655

PAGE analysis of endophyte-infected leaf sheath extract and BSA in the presence of a reductant or of inhibitors PMSF (col 3, 60-65). Since the reference does not mention that the crude membrane fraction of Fungus *Acremonium typhinum* is encapsulated, it is considered as a non-encapsulating adjuvant.

As evidenced by Miller et al (US 6,372, 446), chitin is a major polysaccharide of the cell wall of fungi (col 7, lines 47-51), therefore, it is inherent that an yeast extract contains chitin.

Applicant is requested to note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., Ex Parte Masham, 2 USPQ2d 1647 (1987) and In Re Hack 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Therefore, the reference is deemed to anticipate the instant claim above.

Claims 1-4, 7, 8, 12, and 18 are rejected under 35 USC § 102 (e) as being anticipated by Breton et al (US 2005/0069505).

Breton et al teach a composition for photoprotection of the skin (for use as a medicament) comprising at least one probiotic lactic acid (pharmaceutically active compound, having hydrophilic moiety) bacterium and at least one carotenoid or derivative (pharmaceutically active compound) (see Abstract). The composition further comprises yeast extract selected from *Ascomycotina* or *Saccharomyces caerevisiae* (p0027). Since the reference does not mention that

Art Unit: 1655

the yeast extract (contains a fungal cell or fragment) is encapsulated, it is considered as a non-encapsulating adjuvant.

As evidenced by Miller et al (US 6,372, 446), chitin is a major polysaccharide of the cell wall of fungi (col 7, lines 47-51), therefore, it is inherent that an yeast extract contains chitin.

Applicant is requested to note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., Ex Parte Masham, 2 USPQ2d 1647 (1987) and In Re Hack 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Therefore, the reference is deemed to anticipate the instant claim above.

### **Claim Rejections –35 USC § 103**

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-8, and 12-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Belanger et al (US 5,443,981) in view of Modi (US 6,221,378).

Belanger et al teach a crude membrane fraction of Fungus *Acremonium typhinum* (contains a fungal cell or fragment) exhibiting endoproteolytic activity which has a function of insect deterrence (thus a medicament)(col 1, lines 45-50), and the fraction is reactive with BCA (pharmaceutically active compound, peptide, having a hydrophilic moiety). The endoproteolytic activity is inhibited by the protease inhibitor PMSF (col 1, lines 60-67). Fig. 4 shows the SDS-PAGE analysis endophyte-infected leaf sheath extract and BSA in the presence of a reductant or of inhibitors PMSF (col 3, 60-65). Since the reference does not mention that the crude membrane fraction of Fungus *Acremonium typhinum* is encapsulated, it is considered as a non-encapsulating adjuvant.

As evidenced by Miller et al (US 6,372, 446), chitin is a major polysaccharide of the cell wall of fungi (col 7, lines 47-51), therefore, it is inherent that an yeast extract contains chitin.

Belanger et al do not teach paracellular pathway, encapsulation, and claimed amount of chitin/chitosan.

Modi teaches protein drug was encapsulated in mixed micelles which allows opening of paracellular junctions with high degree of protease activity preserved and protecting molecules from premature degradation in the hostile acidic and proteolytic GI environment (*in vivo*), and overcoming the problem of the bitter taste and irritation of the drug (col 2, lines 58-67; col 3, lines 1-5).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to use the encapsulation technique to enhance the paracellular permeability of Modi in Belanger et al since Modi teaches that the delivery system has high

Art Unit: 1655

degree of protease activity preserved and it can protect molecules from premature degradation in the hostile acidic and proteolytic GI environment (*in vivo*), and it overcomes the problem of the bitter taste and irritation of the drug (col 2, lines 58-67; col 3, lines 1-5). Since the invention of Modi yielded beneficial results in drug delivery system, one of ordinary skill in the art would have been motivated to make the modifications. The result-effective adjustment in conventional working parameters (e.g., determining an appropriate amount of the components within the composition) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

From the teachings of the references, it is apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention.

Applicant is requested to note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., *Ex Parte Masham*, 2 USPQ2d 1647 (1987) and *In Re Hack* 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.



Art Unit: 1655

Claims 1-4, 7, 8, and 12-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Breton et al (US 2005/0069505) in view of Modi (US 6,221,378).

Breton et al teach a composition for photoprotection of the skin (for use as a medicament) comprising at least one probiotic lactic acid (pharmaceutically active compound, having hydrophilic moiety) bacterium and at least one carotenoid or derivative (pharmaceutically active compound) (see Abstract). The composition further comprises yeast extract selected from *Ascomycotina* or *Saccharomyces caerevisae* (p0027). Since the reference does not mention that the yeast extract (contains a fungal cell or fragment) is encapsulated, it is considered as a non-encapsulating adjuvant.

As evidenced by Miller et al (US 6,372, 446), chitin is a major polysaccharide of the cell wall of fungi (col 7, lines 47-51), therefore, it is inherent that an yeast extract contains chitin.

Breton et al do not teach paracellular pathway, encapsulation, and claimed amount of chitin/chitosan.

Modi teaches protein drug was encapsulated in mixed micelles which allows opening of paracellular junctions with high degree of protease activity preserved and protecting molecules from premature degradation in the hostile acidic and proteolytic GI environment (*in vivo*), and overcoming the problem of the bitter taste and irritation of the drug (col 2, lines 58-67; col 3, lines 1-5).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to use the encapsulation technique to enhance the paracellular

Art Unit: 1655

permeability of Modi in Breton et al since Modi teaches that the delivery system has high degree of protease activity preserved and it can protect molecules from premature degradation in the hostile acidic and proteolytic GI environment (*in vivo*), and it overcomes the problem of the bitter taste and irritation of the drug (col 2, lines 58-67; col 3, lines 1-5). Since the invention of Modi yielded beneficial results in drug delivery system, one of ordinary skill in the art would have been motivated to make the modifications. The result-effective adjustment in conventional working parameters (e.g., determining an appropriate amount of the components within the composition) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan.

From the teachings of the references, it is apparent that one of the ordinary skills in the art would have had a reasonable expectation of success in producing the claimed invention.

Applicant is requested to note that it is regarded that "intended use" of a composition or product will not further limit claims drawn to a composition or product. See, e.g., *Ex Parte Masham*, 2 USPQ2d 1647 (1987) and *In Re Hack* 114, USPQ 161. A recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

### **Conclusion**

Art Unit: 1655

No claim is allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Qiuwen Mi whose telephone number is 571-272-5984. The examiner can normally be reached on 8 to 5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on 571-272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



**MICHAEL MELLER**  
**PRIMARY EXAMINER**